Treatment of adult patients w/ locally advanced or metastatic breast cancer who have progressed after at least 1 chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline & a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments. Treatment of adult patients w/ unresectable liposarcoma who have received prior anthracycline-containing therapy (unless unsuitable) for advanced or metastatic disease.
1.23 mg/m2 IV over 2-5 min on days 1 & 8 of every 21-day cycle. Mild hepatic impairment 0.97 mg/m2 IV over 2-5 min on days 1 & 8 of a 21-day cycle. Moderate hepatic impairment 0.62 mg/m2 IV over 2-5 min on days 1 & 8 of a 21-day cycle.
Myelosuppression. Monitor complete blood counts prior to each dose. Febrile neutropenia, neutropenic sepsis, sepsis & septic shock; severe neutropenia, thrombocytopenia. Patient w/ ALT & AST >3 x ULN or w/ bilirubin >1.5 x ULN; preexisting neuropathy grade 1 or 2. Monitor for signs of peripheral motor & sensory neuropathy. ECG monitoring of QT prolongation. Contains small amounts of ethanol (alcohol), <100 mg/dose. May affect ability to drive or operate machinery. Pregnancy, childn & adolescent.
Caution & monitoring for adverse events is recommended w/ concomitant use of substances that have a narrow therapeutic window & that are eliminated mainly via CYP3A4-mediated metabolism (eg, alfentanil, cyclosporine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus).
Sign Out
